What is GALAXY?
GALAXY is a H2020 project that aims to optimize personalized healthcare for patients with liver disease,
by stratifying individuals who would benefit from targeted healthcare efforts versus those who would not,
and thus to reduce the economic burden for health care systems and to improve health outcome for the patients.
GALAXY has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668031
GALAXY results presented at ILC22 in London
On 23 June, Mads Israelsen presents results from the Rifaximin study at the General Session at ILC2022.
GALAXY and MicrobLiver publish together in Nature Medicine
In a comprehensive study, the liver and blood proteome has been systematically identified and characterized, revealing biomarkers with high accuracy for the detection of early-stage liver disease
Costs and benefits of targeting alcohol-related liver disease
Online GALAXY seminar 24 February 3-4.30 pm (CET)
GALAXY researcher receives Novozymes prize
Peer Bork has received the Novozymes Prize 2021 in recognition of the outstanding research he has undertaken during his entire research career. The Prize is accompanied by DKK 5 million and is awarded by the Novo Nordisk Foundation.
New GALAXY publication: Increasingly dysbalanced collagen turnover as fibrosis stage worsen
Maja Thiele on Center for Liver Research's new GALAXY-publication about upregulation of fibrillar collagen formation (PRO-C3) and degradation (C3M) in alcohol-related liver disease.
Last patient – last visit in GALAXY RCT
In August, a very important milestone was reached in the RCT SYN-ALD, when the last patient completed the last visit.
Hepatology for Dummies
7 April, the first Academy Afternoon in the GALAXY and MicrobLiver consortia was hosted by Odense University Hospital.
PhD defence Ditlev Nytoft Rasmussen
26 March, Ditlev Nytoft Rasmussen will defend his PhD on prognostic markers in alcohol-related liver disease.
GALAXY online meeting
1-3 March, GALAXY hosted a 3 days online meeting for all partners together with project MicrobLiver
Multinational collaboration establish common cut-offs for liver stiffness measurements
Finally, researchers have agreed on the interpretation of liver stiffness measurements. There has long been disagreement about which cut-off values to use for transient elastography (FibroScan). With the use of GALAXY data, a multinational collaboration has now established cut-off values to rule in and rule out compensated advanced chronic liver disease across the four major liver disease etiologies.
Inclusion of patients concluded in the fourth GALAXY study
55 patients with alcoholic liver disease are now included in the SYN-ALD a randomized controlled trial in GALAXY.
GALAXY part of multi-centre study published in AP&T
New study shows that digital assistance improves physician’s accuracy to predict who will develop complication to cirrhosis and die from alcohol-related liver disease.
Five abstracts from the GALAXY project was presented on 27-29 August at the Digital International Liver Congress 2020
136 ALD patients included in the Rifaximin trial
In May 2020 an important milestone in the Rifaximin study was reached, since the last of 136 participants was included.
GALAXY Steering Committee Meeting
The GALAXY partners met in Copenhagen for Steering Committee Meeting
Best of the Liver Meeting 2019
GALAXY had two oral presentations at the Liver Meeting 2019 - one was selected as part of Best of Liver Meeting 2019
GALAXY Advisory Board
GALAXY hosted meeting at AASLD in Boston